Altered social interaction in adult rats following neonatal treatment with domoic acid

Physiology and Behavior

Volumn 102, Issue 3-4, 2011, Pages 291-295

  Ryan, Catherine L ^a   Robbins, Mark A ^a   Smith, Meghan T ^a   Gallant, Ian C ^a   Adams Marriott, Amber L ^a   Doucette, Tracy A ^a  

^a UNIVERSITY OF PRINCE EDWARD ISLAND   (Canada)

Author keywords

Animal models; Domoic acid; Glutamate; Neurodevelopmental disorders; Schizophrenia

Indexed keywords

DOMOIC ACID;

ANIMAL EXPERIMENT; ARTICLE; AVOIDANCE BEHAVIOR; CONTROLLED STUDY; FEMALE; MALE; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; PSYCHOSOCIAL WITHDRAWAL; RAT; SCORING SYSTEM; SOCIAL BEHAVIOR; SOCIAL INTERACTION;

ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, NEWBORN; BEHAVIOR, ANIMAL; CRITICAL PERIOD (PSYCHOLOGY); DISEASE MODELS, ANIMAL; EXCITATORY AMINO ACID AGONISTS; FEMALE; GLUTAMIC ACID; KAINIC ACID; MALE; RATS; RATS, SPRAGUE-DAWLEY; SCHIZOPHRENIA; SOCIAL BEHAVIOR;

EID: 78650609181     PISSN: 00319384     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.physbeh.2010.11.020     Document Type: Article

References (63)

1. Bleakman D., Lodge D. Neuropharmacology of AMPA and kainate receptors. Neuropharmacol 1998, 37:1187-1204.
2. Bettler B., Mulle C. Review: neurotransmitter receptors II: AMPA and kainate receptors. Neuropharmacol 1995, 34:123-139.
3. Jorgensen M., Tygesen C.K., Andersen P.H. Ionotropic glutamate receptors - Focus on non-NMDA receptors. Pharmacol Toxicol 1995, 76:312-319.
4. Ozawa S., Kamiya H., Tsuzuki K. Glutamate receptors in the mammalian central nervous system. Prog Neurobiol 1998, 54:581-618.
5. Huettner J.E. Kainate receptors and synaptic transmission. Prog Neurobiol 2003, 70:387-407.
6. Frerking M., Schmitz D., Zhou Q., Johansen J., Nicoll R.A. Kainate receptors depress excitatory synaptic transmission at CA3->CA1 synapses in the hippocampus via a direct presynaptic action. J Neurosci 2001, 21:2958-2966.
7. Lerma J., Paternain A.V., Rodríguez-Moreno A., López-García J.C. Molecular physiology of kainate receptors. Physiol Rev 2001, 81:971-998.
8. Frerking M., Nicoll R.A. Synaptic kainate receptors. Curr Opin Neurobiol 2000, 10:342-351.
9. Bubeníková-Valesová V., Horácek J., Vrajová M., Höschl C. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neurosci Biobehav Rev 2008, 32:1014-1023.
10. Deutsch S.I., Rosse R.B., Schwartz B.L., Mastropaolo J. A revised excitotoxic hypothesis of schizophrenia: therapeutic implications. Clin Neuropharmacol 2001, 24:43-49.
11. Parsons C.G., Danysz W., Quack G. Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect 1998, 11:523-569.
12. Tseng K.Y., Chambers R.A., Lipska B.K. The neonatal ventral hippocampal lesion as a heuristic neurodevelopmental model of schizophrenia. Behav Brain Res 2008, 10.1016/jbbr.2008.11.039.
13. Goeree R., Farahati F., Burke N., Blackhouse G., O'Reilly D., Pyne J. The economic burden of schizophrenia in Canada in 2004. Curr Med Res Opin 2005, 21:2017-2028.
14. Tamminga C.A., Holcomb H.H. Phenotype of schiophrenia: a review and formulation. Mol Psychiatry 2005, 10:27-39.
15. American Psychiatric Association Diagnostic and statistical manual of mental disorders 2000, American Psychiatric Association, Washington DC, (4th ed., text revision).
16. Tandon R., Nasrallah H.A., Keshavan M.S. Schizophrenia just the facts: 4: clinical features and conceptualization. Schizophr Res 2009, 110:1-23.
17. Gold J.M., Harvey P.D. Cognitive deficits in schizophrenia. Psychiatr Clin North Am 1993, 16:295-312.
18. Andreasen N.C., Olsen S. Negative v positive schizophrenia. Definition and validation. Arch Gen Psychiatry 1982, 39:789-794.
19. Strauss J.S., Carpenter W.T., Bartko J.J. The diagnosis and understanding of schizophrenia part III: speculation on the processes that underlie schizophrenia symptoms and signs. Schizophr Bull 1974, 1:61-69.
20. Stone J.M., Morrison P.D., Pilowsky L.S. Glutamate and dopamine dysregulation in schizophrenia-a synthesis and selective review. J Psychopharmacol 2007, 21:440-452.
21. Wong A.H.C., Van Tol H.H.M. Schizophrenia: from phenomenology to neurobiology. Neurosci Biobehav Rev 2003, 27:269-306.
22. Tsai G., Coyle J.T. Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 2002, 42:165-179.
23. Rung J.P., Carlsson A., Rydén Markinhuhta K., Carlsson M.L. (+)-MK-801 induced social withdrawal in rats; a model for negative symptoms of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:827-832.
24. Becker A., Grecksch G. Ketamine induced changes in rat behaviour: a possible animal model of schizophrenia. Test of predictive validity. Program Neurobiol Psychopharmacol Biol Psychiatry 2004, 28:1267-1277.
25. Becker A., Peters B., Schroeder H., Mann T., Huether G., Grecksch G. Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Program Neurobiol Psychopharmacol Biol Psychiatry 2003, 27:687-700.
26. Brambilla P., Riva M., Melcangi R., Diwadkar V. The role of glutamatergic pathways in schizophrenia: from animal models to human imaging studies. Clin Neuropsychiatry 2007, 4:199-207.
27. Olney J.W., Newcomer J.W., Farber N.B. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 1999, 33:523-533.
28. Bickel S., Javitt D.C. Neurophysiological and neurochemical animal models of chizophrenia: focus on glutamate. Behav Brain Res 2008, 10.1016/j.bbr.2009.05.005.
29. Meador-Woodruff J., Healy D. Glutamate receptor expression in schizophrenic brain. Brain Res Rev 2000, 31:288-294.
30. Tzschentke T.M. Pharmacology and behavioural pharmacology of the mesocortical dopamine system. Prog Neurobiol 2001, 63:241-320.
31. Kalivas P.W., Duffy P., Barrow J. Regulation of the mesocorticolimbic dopamine system by glutamic acid receptor subtypes. J Pharmacol Exp Ther 1989, 251:378-387.
32. Wu W.R., Li N., Sorg B.A. Regulation of medial prefrontal cortex dopamine by alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptors. Neuroscience 2002, 114:507-516.
33. Jedema H.P., Moghddam B. Characterization of excitatory amino acid modulation of dopamine release in the prefrontal cortex of conscious rats. J Neurochem 1996, 66:1448-1453.
34. Verdoorn T.A., Johansen T.H., Drejer J., Nielsen E.O. Selective block of recombinant glur6 receptors by NS-102, a novel non-NMDA receptor antagonist. Eur J Pharmacol 1994, 269:43-49.
35. Verdoorn T.A., Burnashev N., Monyer H., Seeburg P.H., Sakmann B. Structural determinants of ion flow through recombinant glutamate receptor channels. Science 1991, 252:1715-1718.
36. Dobbing J., Smart J.L. Vulnerability of developing brain and behaviour. Br Med Bull 1974, 30:164-168.
37. Adams A.L., Doucette T.A., Ryan C.L. Altered pre-pulse inhibition in adult rats treated neonatally with domoic acid. Amino Acids 2008, 35:157-160.
38. Burt M.A., Ryan C.L., Doucette T.A. Altered responses to novelty and drug reinforcement in adult rats treated neonatally with domoic acid. Physiol Behav 2008, 93:327-336.
39. Powell C.M., Miyakawa T. Schizophrenia-relevant behavioral testing in rodent models: a uniquely human disorder?. Biol Psychiatry 2006, 59:1198-1207.
40. Swerdlow N.R., Halim N., Hanlon F.M., Platten A., Auerbach P.P. Lesion size and amphetamine hyperlocomotion after neonatal ventral hippocampal lesions: more is less. Brain Res Bull 2001, 55:71-77.
41. Wood G.K., Lipska B.K., Weinberger D.R. Behavioral changes in rats with early ventral hippocampal damage vary with age at damage. Brain Res Dev Brain Res 1997, 101:17-25.
42. Adams A.L., Doucette T.A., James R., Ryan C.L. Persistent changes in learning and memory in rats following neonatal treatment with domoic acid. Physiol Behav 2009, 96:505-512.
43. Burt M.A., Ryan C.L., Doucette T.A. Low dose domoic acid in neonatal rats abolishes nicotine induced conditioned place preference during late adolescence. Amino Acids 2008, 35:247-249.
44. Doucette T.A., Ryan C.L., Tasker R.A. Gender-based changes in cognition and emotionality in a new rat model of epilepsy. Amino Acids 2007, 32:317-322.
45. Kato T., Kubota M., Kasahara T. Animal models of bipolar disorder. Neurosci Biobehav Rev 2007, 31:832-842.
46. Ellenbroek B.A., Cools A.R. Animal models for the negative symptoms of schizophrenia. Behav Pharmacol 2000, 11:223-233.
47. Doucette T.A., Bernard P.B., Husum H., Perry M.A., Ryan C.L., Tasker R.A. Low doses of domoic acid during postnatal development produce permanent changes in rat behaviour and hippocampal morphology. Neurotox Res 2004, 6:555-563.
48. Doucette T.A., Bernard P.B., Yuill P.C., Tasker R.A., Ryan C.L. Low doses of non-NMDA glutamate receptor agonists alter neurobehavioural development in the rat. Neurotoxicol Teratol 2003, 25:473-479.
49. Doucette T.A., Strain S.M., Allen G.V., Ryan C.L., Tasker R.A. Comparative behavioural toxicity of domoic acid and kainic acid in neonatal rats. Neurotoxicol Teratol 2000, 22:863-869.
50. Tasker R.A., Perry M.A., Doucette T.A., Ryan C.L. NMDA receptor involvement in the effects of low dose domoic acid in neonatal rats. Amino Acids 2005, 28:193-196.
51. Crawley J.N. Mouse behavioural assays relevant to the symptoms of autism. Brain Pathol 2007, 17:448-459.
52. Sams-Dodd F. Phencyclidine in the social interaction test: an animal model of schizophrenia with face and predictive validity. Rev Neurosci 1999, 10:59-90.
53. Sams-Dodd F., Lipska B.K., Weinberger D.R. Neonatal lesions of the rat ventral hippocampus result in hyperlocomotion and deficits in social behaviour in adulthood. Psychopharmacol Berl 1997, 132:303-310.
54. Galanopoulou A.S. Dissociated gender-specific effects of recurrent seizures on GABA signaling in CA1 pyramidal neurons: role of GABA(A) receptors. J Neurosci 2008, 28:557-1567.
55. Galanopoulou A.S. Sexually dimorphic expression of KCC2 and GABA function. Epilepsy Res 2008, 80:99-113.
56. Nuñez J.L., McCarthy M.M. Evidence for an extended duration of GABA-mediated excitation in the developing male versus female hippocampus. Dev Neurobiol 2007, 67(14):1879-1890.
57. Kyrozis A., Chudomel O., Moshe S.L., Galanopoulou A.S. Sex-dependent maturation of GABAA receptor mediated synaptic events in rat substantia nigra reticulata. Neurosci Lett 2006, 398:1-5.
58. Lemmens E.M., Lubbers T., Schijns O.E., Beuls E.A., Hoogland G. Gender differences in febrile seizure-induced proliferation and survival in the rat dentate gyrus. Epilepsia 2005, 46:1603-1612.
59. Barna B., Kuhnt U., Siklos L. Chloride distribution in the CA1 region of newborn and adult hippocampus by light microscopic histochemistry. Histochem Cell Biol 2001, 115:105-116.
60. Ganguly K., Schinder A.F., Wong S.T., Poo M. GABA itself promotes the developmental switch of neuronal GABAergic responses from excitation to inhibition. Cell 2001, 105:521-532.
61. Leung A., Chue P. Sex differences in schizophrenia, a review of the literature. Acta Psychiatr Scand Suppl 2000, 401:3-38.
62. Castle D.J., Wessely S., Murray R.M. Sex and schizophrenia: effects of diagnostic stringency, and associations with and premorbid variables. Br J Psychiatry 1993, 162:658-664.
63. Silva-Gómez A.B., Bermudez M., Quirion R., Srivastava L.K., Picazo O., Flores G. Comparative behavioral changes between male and female postpubertal rats following neonatal excitotoxic lesions of the ventral hippocampus. Brain Res 2003, 973:285-292.